The modeled fair value for ORIC Pharmaceuticals moved from US$20.67 to US$21.93, a small change tied to analyst views on enozertinib and rinzimetostat. Several firms, including Stifel, JPMorgan and H.C. Wainwright, raised price targets into a US$18 to US$27 range, with JPMorgan describing enozertinib as an underappreciated driver. BTIG and Leerink initiated coverage with US$26 targets, while one analyst noted the stock was down 5% at US$12.89 in morning trading on the day of the lung cancer data update. The fair value model also changed the net profit margin assumption from 17.25% to 15.91% and the future P/E from 753.08x to 971.94x.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsvaluationclinical trials
Open a keyword to see other news on the same topic.
Related news
- argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
argenx reported third-quarter 2026 global product net sales of VYVGART of $1.7 billion, up 54% year over year and 13% quarter over quarter. Positive Phase 3 ALKIVIA results showed consistent treatment effects in IMNM and dermatomyositis, with an sBLA for IMNM on track for submission by year-end 2026. The company submitted an sBLA for ocular myasthenia gravis to the FDA, and a pediatric gMG sBLA was accepted for priority review with a PDUFA target date in February 2027. Phase 3 EMPASSION topline results for empasiprubart in MMN are expected in December 2026, while FB102 is advancing to Phase 3 in celiac disease. argenx continues to target treating 50,000 patients, securing 10 labeled indications and advancing five candidates into registrational development by 2030.
- Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Viking Therapeutics has started two phase 3 trials, SUNRISE-1 and SUNRISE-2, for the oral form of its weight loss drug VK2735, alongside its ongoing injectable phase 3 trials. Investors had been shaken by the phase 2 oral trial (VENTURE-Oral), where 20% of treated participants discontinued due to adverse events and the stock fell sharply, although efficacy over 13 weeks was good. The author argues the phase 3 design is different: 13% of the phase 2 placebo group also stopped due to adverse events, phase 2 used a more aggressive titration, and phase 3 runs 68 weeks. CEO Brian Lian said that in phase 2 patients took 4 tablets that were fairly large, and phase 3 aims for smaller tablets and fewer of them. Phase 3 doses are also lower, at 27.5 mg, 35 mg and 55 mg, compared with 15 mg to 120 mg in phase 2.
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- Syndax Pharmaceuticals (SNDX) Is Down 7.2% After Axatilimab IPF Trial Misses Endpoint Has The Bull Case Changed?
Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint of slowing lung function decline, so it will halt further IPF development for the drug while other trials continue. Safety in IPF was comparable to placebo, and ongoing studies and the approved chronic GVHD use of Niktimvo are unaffected. The article views the setback as a narrowing of axatilimab's opportunity rather than a franchise-level issue, with Revuforj and Niktimvo still the core commercial pillars. However, Syndax remains loss-making and spends roughly US$400 million a year on R&D and SG&A, so revenue growth is the key factor to watch.
- 3 Dirt Cheap Dividend Stocks to Buy Hand Over Fist
The article argues that Pfizer, T. Rowe Price and Verizon look undervalued because the market is overreacting to their headwinds, while the S&P 500 trades at 23.5 times earnings with a 1.1% yield. Pfizer trades at 9.6 times forward earnings and offers a 5.6% dividend yield with a payout ratio just under 60%, though revenue and earnings have declined since 2022 and patent expirations such as Eliquis are pressuring shares. T. Rowe Price has a 5% forward dividend yield, a 40-year record of consecutive dividend growth and trades at 10 times forward earnings, and its pivot toward ETFs could soften the impact of a market downturn. Verizon added 550,000 net customer additions in mobility and broadband in the second quarter of 2026, but its shares have slumped on concerns about SpaceX's satellite services, and it has a 6.2% forward dividend yield at less than 9 times forward earnings.
- AstraZeneca offers compelling risk-reward into 2027 pipeline readouts, says JPMorgan
JPMorgan says AstraZeneca (LSE:AZN, NYSE:AZN) offers a compelling risk-reward opportunity ahead of late-stage readouts in 2027, which could collectively unlock more than $20 billion in non-risk-adjusted peak sales. Key studies include laroprovstat, Farxiga combinations, Datroway, puxi-sam, camizestrant and saruparib. The AVANZAR trial of Datroway has moved to Q1 2027 from Q4 2026 because progression-free survival events have not yet accumulated; JPMorgan says this could raise confidence in success, particularly in patients with the TROP2 biomarker. The stock trades at around 15 times 2027 earnings, broadly in line with European pharma, and the broker sees this as attractive given expected core earnings growth of around 10% over 2027-2030, roughly 40% ahead of the sector.
Related markets
Latest news
- Bitcoin Treasury Datavault AI Says It Can’t Access Its BTC, Stock Tanks
Datavault AI shares fell 49.55% to $0.067 after an SEC filing said the company has been unable since June to complete a request to withdraw Bitcoin from the Biconomy exchange. The company will restate four financial reports, cutting reported assets by up to $92.2 million, after reclassifying Bitcoin from a $150 million Scilex stock deal as a subscription receivable. Management is reassessing its going-concern status because it had counted the Bitcoin as a source of liquidity, and collecting what Scilex owes is uncertain. Scilex separately signed a binding term sheet in June 2026 to buy 837 BTC held in Datavault's Biconomy wallet for $50 million, subject to a definitive agreement. Datavault stock later bounced to near $0.085.
- Carvana and Chipotle Soar After Earnings While Ford and ServiceNow Sink
Carvana sold a record number of cars and Chipotle's traffic held up, sending both stocks higher after hours. Ford's EV losses and a small ServiceNow miss weighed on those two stocks.
- AI Spending Is Nearing $1 Trillion Annually. These 2 Stocks Are Most at Risk If It Slows.
AI capital expenditures are approaching $1 trillion a year, driving record results at Nvidia and Micron but raising investor doubts about how sustainable the spending is. Nvidia reported $96.2 billion in revenue for its fiscal 2027 second quarter, with $89 billion from its data center business, so its growth is closely tied to the AI infrastructure budgets of the biggest tech companies. Micron benefits from strong high bandwidth memory demand, reporting fiscal 2026 fourth-quarter revenue of $54.2 billion and $133.2 billion for the full year, but memory is cyclical and an oversupply could push prices down. The article concludes that both companies could be reassessed if AI spending slows, with Nvidia having more to lose.
- Alphabet CFO walks through the company's Q3 results
Alphabet (GOOGL, GOOG) CFO Anat Ashkenazi outlined the company's third-quarter financial results on its Q3 earnings call. The call covered revenue growth, operating expense growth driven by AI talent and Gemini investment, and a jump in operating income.
- Canadian ‘crypto king’ case to go to jury as criminal trial winds down
Aiden Pleterski, a self-described “crypto king” in Canada, faces fraud charges over his alleged role in a digital asset Ponzi scheme, and the case will go to jury deliberations after closing arguments. Pleterski told the court he is innocent, saying he was forced to represent himself and that his innocence would otherwise have been proven. According to CBC, the jury will begin deliberating Thursday after receiving final instructions from Justice Shaun Nakatsuru. He is accused of defrauding about $30 million from social media followers between 2021 and 2022, was charged in 2024, and had waited more than two years for trial; a fraud conviction could bring up to 14 years in prison. Separately, five men, some reportedly victims of the scheme, were charged with kidnapping and torturing him in 2022, and one of them, Deren Akyeam-Pong, pleaded guilty to nine charges and awaits sentencing.
- Microsoft recorded $10 billion in revenue from OpenAI
Microsoft reported $10 billion in revenue from its commercial arrangements with OpenAI, including revenue-sharing payments, in the quarter ended September 30, nearly 11% of its $92.3 billion total quarterly revenue. For the full 2026 fiscal year, OpenAI-related revenue reached $24.1 billion, and at the latest quarterly pace Microsoft would earn about $40 billion a year from these arrangements. Its receivables from OpenAI rose to $7.2 billion at the end of September from $6 billion at the end of June, reflecting amounts owed for past transactions rather than new revenue. The filing does not show how much came from revenue sharing versus Azure cloud services. Under an April 2026 agreement, OpenAI will keep sharing revenue with Microsoft through 2030, subject to a cap, while Microsoft's stake fell from about 25% in June to 24% in September, with no cause specified.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.